Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of “Hold” from Analysts

Certara, Inc. (NASDAQ:CERT) has received an average recommendation of “Hold” from the ten research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $18.56.

Several research firms have weighed in on CERT. Barclays dropped their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. UBS Group lowered their price objective on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday. Robert W. Baird lowered their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Finally, KeyCorp lowered their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th.

Certara Price Performance

Shares of Certara stock traded down $0.56 on Friday, hitting $12.51. The company’s stock had a trading volume of 1,559,225 shares, compared to its average volume of 582,396. The company has a market capitalization of $2.01 billion, a P/E ratio of -32.08, a price-to-earnings-growth ratio of 5.39 and a beta of 1.52. Certara has a 52-week low of $11.81 and a 52-week high of $19.87. The firm has a fifty day moving average price of $14.93 and a 200-day moving average price of $16.47. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. On average, equities research analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of large investors have recently added to or reduced their stakes in CERT. Blue Trust Inc. purchased a new position in Certara in the 2nd quarter valued at about $26,000. Pineridge Advisors LLC acquired a new stake in shares of Certara in the 4th quarter valued at about $28,000. Global Retirement Partners LLC raised its stake in shares of Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after purchasing an additional 1,698 shares in the last quarter. Innealta Capital LLC bought a new position in shares of Certara during the second quarter worth about $36,000. Finally, YHB Investment Advisors Inc. acquired a new position in Certara in the first quarter worth about $47,000. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.